<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39444602</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Emerging small-molecule antiviral agents in long COVID prevention.</ArticleTitle><Pagination><StartPage>1457672</StartPage><MedlinePgn>1457672</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1457672</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2024.1457672</ELocationID><Abstract><AbstractText>Long COVID, or Post-Acute Sequelae of COVID-19 (PASC), was characterized by persistent symptoms such as fatigue, shortness of breath, and cognitive impairments. These symptoms, emerging one to 2&#xa0;months post-infection and persisting for several months, cannot be attributed to other diagnoses. The pathophysiology of long COVID remained elusive; however, emerging studies suggested multiple potential mechanisms, including the reactivation of Epstein-Barr virus, persistent SARS-CoV-2 reservoirs, neuroinflammation, and vascular damage, which may contribute to its development. Long COVID affected multiple organ systems, including respiratory, circulatory, and nervous systems, leading to a range of functional impairments. Additionally, it showed a profound impact on mental health, manifesting as anxiety and depression, which significantly degraded the quality of life. The absence of definitive treatments underscored the importance of prevention. Recent evidence indicated that early antiviral intervention-particularly with small-molecule drugs such as Metformin, Ensitrelvir, Molnupiravir, and Nirmatrelvir-may effectively reduce the incidence of long COVID. This underscored the promising role of small-molecule compounds in mitigating long-term COVID-19 consequences, offering a novel preventive strategy against long COVID and its extensive impacts on patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 He, Zhang and Zhong.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Xiaomeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Blood Transfusion Medicine, The 940th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Wu</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ensitrelvir</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">metformin</Keyword><Keyword MajorTopicYN="N">molnupiravir</Keyword><Keyword MajorTopicYN="N">nirmatrelvir</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>16</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>16</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39444602</ArticleId><ArticleId IdType="pmc">PMC11496125</ArticleId><ArticleId IdType="doi">10.3389/fphar.2024.1457672</ArticleId><ArticleId IdType="pii">1457672</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Altmann D. M., Whettlock E. M., Liu S., Arachchillage D. J., Boyton R. J. (2023). The immunology of long COVID. Nat. Rev. Immunol. 23 (10), 618&#x2013;634. 10.1038/s41577-023-00904-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-023-00904-7</ArticleId><ArticleId IdType="pubmed">37433988</ArticleId></ArticleIdList></Reference><Reference><Citation>Appelman B., Charlton B. T., Goulding R. P., Kerkhoff T. J., Breedveld E. A., Noort W., et al. (2024). Muscle abnormalities worsen after post-exertional malaise in long COVID. Nat. Commun. 15 (1), 17. 10.1038/s41467-023-44432-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-44432-3</ArticleId><ArticleId IdType="pmc">PMC10766651</ArticleId><ArticleId IdType="pubmed">38177128</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker J. H., Lin J. J., Doernberg M., Stone K., Navis A., Festa J. R., et al. (2021). Assessment of cognitive function in patients after COVID-19 infection. JAMA Netw. Open 4 (10), e2130645. 10.1001/jamanetworkopen.2021.30645</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.30645</ArticleId><ArticleId IdType="pmc">PMC8536953</ArticleId><ArticleId IdType="pubmed">34677597</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertuccio P., Degli Antoni M., Minisci D., Amadasi S., Castelli F., Odone A., et al. (2023). The impact of early therapies for COVID-19 on death, hospitalization and persisting symptoms: a retrospective study. Infection 51, 1633&#x2013;1644. 10.1007/s15010-023-02028-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-023-02028-5</ArticleId><ArticleId IdType="pmc">PMC10079146</ArticleId><ArticleId IdType="pubmed">37024626</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante C. T., Buse J. B., Liebovitz D. M., Nicklas J. M., Puskarich M. A., Cohen K., et al. (2023). Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect. Dis. 23 (10), 1119&#x2013;1129. 10.1016/S1473-3099(23)00299-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00299-2</ArticleId><ArticleId IdType="pmc">PMC11259948</ArticleId><ArticleId IdType="pubmed">37302406</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan A. T. (2016). Metformin for cancer prevention: a reason for optimism. Lancet Oncol. 17 (4), 407&#x2013;409. 10.1016/S1470-2045(16)00006-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(16)00006-1</ArticleId><ArticleId IdType="pubmed">26947330</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P., Wu M., He Y., Jiang B., He M. L. (2023). Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection. Signal Transduct. Target Ther. 8 (1), 237. 10.1038/s41392-023-01510-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01510-8</ArticleId><ArticleId IdType="pmc">PMC10244875</ArticleId><ArticleId IdType="pubmed">37286535</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J., Jansari V., Hornig M., Iwasaki A. (2022). Unexplained post-acute infection syndromes. Nat. Med. 28 (5), 911&#x2013;923. 10.1038/s41591-022-01810-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01810-6</ArticleId><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Coll A. P., Chen M., Taskar P., Rimmington D., Patel S., Tadross J. A., et al. (2020). GDF15 mediates the effects of metformin on body weight and energy balance. Nature 578 (7795), 444&#x2013;448. 10.1038/s41586-019-1911-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1911-y</ArticleId><ArticleId IdType="pmc">PMC7234839</ArticleId><ArticleId IdType="pubmed">31875646</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H. E., McCorkell L., Vogel J. M., Topol E. J. (2023). Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 21 (3), 133&#x2013;146. 10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Demb J., Yaseyyedi A., Liu L., Bustamante R., Earles A., Ghosh P., et al. (2019). Metformin is associated with reduced odds for colorectal cancer among persons with diabetes. Clin. Transl. Gastroenterol. 10 (11), e00092. 10.14309/ctg.0000000000000092</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ctg.0000000000000092</ArticleId><ArticleId IdType="pmc">PMC6890275</ArticleId><ArticleId IdType="pubmed">31770138</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld M. S., Peluso M. J., Lin F., Peyser N. D., Isasi C., Carton T. W., et al. (2024). Association of nirmatrelvir for acute SARS-CoV-2 infection with subsequent Long COVID symptoms in an observational cohort study. J. Med. Virology 96 (1), e29333. 10.1002/jmv.29333</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.29333</ArticleId><ArticleId IdType="pmc">PMC10786003</ArticleId><ArticleId IdType="pubmed">38175151</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerstein H. C., Pare G., Hess S., Ford R. J., Sjaarda J., Raman K., et al. (2017). Growth differentiation factor 15 as a novel biomarker for metformin. Diabetes Care 40 (2), 280&#x2013;283. 10.2337/dc16-1682</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc16-1682</ArticleId><ArticleId IdType="pubmed">27974345</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene C., Connolly R., Brennan D., Laffan A., O&#x2019;Keeffe E., Zaporojan L., et al. (2024). Blood&#x2013;brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment. Nat. Neurosci. 27 (3), 421&#x2013;432. 10.1038/s41593-024-01576-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-024-01576-9</ArticleId><ArticleId IdType="pmc">PMC10917679</ArticleId><ArticleId IdType="pubmed">38388736</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabinger F., Stiller C., Schmitzova J., Dienemann C., Kokic G., Hillen H. S., et al. (2021). Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat. Struct. Mol. Biol. 28 (9), 740&#x2013;746. 10.1038/s41594-021-00651-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-021-00651-0</ArticleId><ArticleId IdType="pmc">PMC8437801</ArticleId><ArticleId IdType="pubmed">34381216</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelleni M. T. (2024). Repurposing metformin to manage idiopathic or long COVID Tinnitus: self-report adopting a pathophysiological and pharmacological approach. Inflammopharmacology 32 (2), 945&#x2013;948. 10.1007/s10787-023-01421-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-023-01421-8</ArticleId><ArticleId IdType="pmc">PMC11006725</ArticleId><ArticleId IdType="pubmed">38294616</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y. S., Choi E. A., Lee J. W., Kim Y., You H. S., Han Y. E., et al. (2020). Metformin use reduced the overall risk of cancer in diabetic patients: a study based on the Korean NHIS-HEALS cohort. Nutr. Metab. Cardiovasc Dis. 30 (10), 1714&#x2013;1722. 10.1016/j.numecd.2020.05.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.numecd.2020.05.010</ArticleId><ArticleId IdType="pubmed">32753274</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J., Wood J., Jaycox J. R., Dhodapkar R. M., Lu P., Gehlhausen J. R., et al. (2023). Distinguishing features of long COVID identified through immune profiling. Nature 623 (7985), 139&#x2013;148. 10.1038/s41586-023-06651-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06651-y</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H. (2022). Long-COVID treatments: why the world is still waiting. Nature 608 (7922), 258&#x2013;260. 10.1038/d41586-022-02140-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-02140-w</ArticleId><ArticleId IdType="pubmed">35945375</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H. (2024). Long COVID is a double curse in low-income nations &#x2014; here&#x2019;s why. Nature 625 (7993), 20&#x2013;22. 10.1038/d41586-023-04088-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-023-04088-x</ArticleId><ArticleId IdType="pubmed">38172361</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M. H., Perl D. P., Nair G., Li W., Maric D., Murray H., et al. (2021). Microvascular injury in the brains of patients with covid-19. N. Engl. J. Med. 384 (5), 481&#x2013;483. 10.1056/NEJMc2033369</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2033369</ArticleId><ArticleId IdType="pmc">PMC7787217</ArticleId><ArticleId IdType="pubmed">33378608</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M. H., Perl D. P., Steiner J., Pasternack N., Li W., Maric D., et al. (2022). Neurovascular injury with complement activation and inflammation in COVID-19. Brain 145 (7), 2555&#x2013;2568. 10.1093/brain/awac151</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac151</ArticleId><ArticleId IdType="pmc">PMC9278212</ArticleId><ArticleId IdType="pubmed">35788639</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateu L., Tebe C., Loste C., Santos J. R., Llad&#xf3;s G., L&#xf3;pez C., et al. (2023). Determinants of the onset and prognosis of the post-COVID-19 condition: a 2-year prospective observational cohort study. Lancet Regional Health - Eur. 33, 100724. 10.1016/j.lanepe.2023.100724</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2023.100724</ArticleId><ArticleId IdType="pmc">PMC10636281</ArticleId><ArticleId IdType="pubmed">37954002</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrath L. J., Scott A. M., Surinach A., Chambers R., Benigno M., Malhotra D. (2022). Use of the postacute sequelae of COVID-19 diagnosis code in routine clinical practice in the US. JAMA Netw. Open 5 (10), e2235089. 10.1001/jamanetworkopen.2022.35089</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.35089</ArticleId><ArticleId IdType="pmc">PMC9539719</ArticleId><ArticleId IdType="pubmed">36201207</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M., Blish C. A., Sallusto F., Iwasaki A. (2022). The immunology and immunopathology of COVID-19. Science 375 (6585), 1122&#x2013;1127. 10.1126/science.abm8108</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm8108</ArticleId><ArticleId IdType="pubmed">35271343</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita Y., Nogami M., Sakaguchi K., Okada Y., Hirota Y., Sugawara K., et al. (2020). Enhanced release of glucose into the intraluminal space of the intestine associated with metformin treatment as revealed by [(18)F]fluorodeoxyglucose PET-MRI. Diabetes Care 43 (8), 1796&#x2013;1802. 10.2337/dc20-0093</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-0093</ArticleId><ArticleId IdType="pubmed">32493754</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Institutes of Health (2024). COVID-19 treatment guidelines panel. Available at: https://www.covid19treatmentguidelines.nih.gov/(Accessed June 27, 2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">34003615</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M. J., Deveau T. M., Munter S. E., Ryder D., Buck A., Beck-Engeser G., et al. (2023). Chronic viral coinfections differentially affect the likelihood of developing long COVID. J. Clin. Invest. 133 (3), e163669. 10.1172/JCI163669</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI163669</ArticleId><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Penlioglou T., Papachristou S., Papanas N. (2020). COVID-19 and diabetes mellitus: may old anti-diabetic agents become the new philosopher's stone? Diabetes Ther. 11 (6), 1195&#x2013;1197. 10.1007/s13300-020-00830-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13300-020-00830-0</ArticleId><ArticleId IdType="pmc">PMC7204191</ArticleId><ArticleId IdType="pubmed">32382358</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C., Jacka B., Ballouz S., Jackson K. J. L., Wilson D. B., Manandhar B., et al. (2024). Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection. Nat. Commun. 15 (1), 3315. 10.1038/s41467-024-47720-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-47720-8</ArticleId><ArticleId IdType="pmc">PMC11024141</ArticleId><ArticleId IdType="pubmed">38632311</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasa S., Nora-Krukle Z., Henning N., Eliassen E., Shikova E., Harrer T., et al. (2018). Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). J. Transl. Med. 16 (1), 268. 10.1186/s12967-018-1644-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-018-1644-y</ArticleId><ArticleId IdType="pmc">PMC6167797</ArticleId><ArticleId IdType="pubmed">30285773</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma S., Ray A., Sadasivam B. (2020). Metformin in COVID-19: a possible role beyond diabetes. Diabetes Res. Clin. Pract. 164, 108183. 10.1016/j.diabres.2020.108183</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2020.108183</ArticleId><ArticleId IdType="pmc">PMC7190487</ArticleId><ArticleId IdType="pubmed">32360697</ArticleId></ArticleIdList></Reference><Reference><Citation>Shestakova M. V., Vikulova O. K., Isakov Mcapital A C., Dedov I. I. (2020). Diabetes and COVID-19: analysis of the clinical outcomes according to the data of the Russian diabetes registry. Probl. Endokrinol. Mosk. 66 (1), 35&#x2013;46. 10.14341/probl12458</Citation><ArticleIdList><ArticleId IdType="doi">10.14341/probl12458</ArticleId><ArticleId IdType="pubmed">33351311</ArticleId></ArticleIdList></Reference><Reference><Citation>
Shionogi and Co., Ltd (2023). Shionogi presents pivotal Ensitrelvir fumaric Acid phase 3 data and exploratory long COVID data at CROI. Available at: https://www.shionogi.com/global/en/news/2023/02/20230222.html (Accessed June 27, 2024).</Citation></Reference><Reference><Citation>
Shionogi and Co., Ltd (2024a). Shionogi announces Xocova&#xae; (Ensitrelvir fumaric Acid) obtained standard approval in Japan for the treatment of SARS-CoV-2 infection. Available at: https://www.shionogi.com/global/en/news/2024/03/20240305.html (Accessed June 28, 2024).</Citation></Reference><Reference><Citation>
Shionogi and Co., Ltd (2024b). Shionogi provides updates from SCORPIO-HR, a global phase 3 study of Ensitrelvir for non-hospitalized participants with COVID-19. Available at: https://www.shionogi.com/global/en/news/2024/05/E_20240513_1.html (Accessed September 2, 2024).</Citation></Reference><Reference><Citation>Spudich S., Nath A. (2022). Nervous system consequences of COVID-19. Science 375 (6578), 267&#x2013;269. 10.1126/science.abm2052</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm2052</ArticleId><ArticleId IdType="pubmed">35050660</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T., Jolley S. E., Karlson E. W., Levitan E. B., Levy B., McComsey G. A., et al. (2023). Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA 329, 1934&#x2013;1946. 10.1001/jama.2023.8823</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.8823</ArticleId><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Unoh Y., Uehara S., Nakahara K., Nobori H., Yamatsu Y., Yamamoto S., et al. (2022). Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J. Med. Chem. 65 (9), 6499&#x2013;6512. 10.1021/acs.jmedchem.2c00117</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.2c00117</ArticleId><ArticleId IdType="pmc">PMC8982737</ArticleId><ArticleId IdType="pubmed">35352927</ArticleId></ArticleIdList></Reference><Reference><Citation>Wargny M., Potier L., Gourdy P., Pichelin M., Amadou C., Benhamou P. Y., et al. (2021). Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. Diabetologia 64 (4), 778&#x2013;794. 10.1007/s00125-020-05351-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-020-05351-w</ArticleId><ArticleId IdType="pmc">PMC7890396</ArticleId><ArticleId IdType="pubmed">33599800</ArticleId></ArticleIdList></Reference><Reference><Citation>Willyard C. (2023). Are repeat COVID infections dangerous? What the science says. Nature 616 (7958), 650&#x2013;652. 10.1038/d41586-023-01371-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-023-01371-9</ArticleId><ArticleId IdType="pubmed">37100944</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organisation (2024). RA02 Post COVID-19 condition. Available at: https://icd.who.int/browse/2024-01/foundation/en#2024855916 (Accessed June 27, 2024).</Citation></Reference><Reference><Citation>Wu H., Esteve E., Tremaroli V., Khan M. T., Caesar R., Manneras-Holm L., et al. (2017). Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med. 23 (7), 850&#x2013;858. 10.1038/nm.4345</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4345</ArticleId><ArticleId IdType="pubmed">28530702</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Choi T., Al-Aly Z. (2023a). Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern Med. 183 (6), 554&#x2013;564. 10.1001/jamainternmed.2023.0743</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0743</ArticleId><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Choi T., Al-Aly Z. (2023b). Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. BMJ 381, e074572. 10.1136/bmj-2022-074572</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-074572</ArticleId><ArticleId IdType="pmc">PMC10126525</ArticleId><ArticleId IdType="pubmed">37161995</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L., She Z. G., Cheng X., Qin J. J., Zhang X. J., Cai J., et al. (2020). Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 31 (6), 1068&#x2013;1077. 10.1016/j.cmet.2020.04.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2020.04.021</ArticleId><ArticleId IdType="pmc">PMC7252168</ArticleId><ArticleId IdType="pubmed">32369736</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>